Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
M Ramachandran, A Vaccaro, T van de Walle… - Cancer Cell, 2023 - cell.com
Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …
In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence
D Nie, Y Ling, W Lv, Q Liu, S Deng, J Shi, J Yang… - ACS …, 2023 - ACS Publications
Glioblastoma (GBM) is one of the most challenging malignant brain tumors to treat. Herein,
we describe a nanoenzyme hemostatic matrix strategy with the tumor cavity in situ …
we describe a nanoenzyme hemostatic matrix strategy with the tumor cavity in situ …
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Radiation therapy (RT) provides therapeutic benefits for patients with glioblastoma (GBM),
but inevitably induces poorly understood global changes in GBM and its microenvironment …
but inevitably induces poorly understood global changes in GBM and its microenvironment …
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor
epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early …
epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early …
Advances in glioblastoma therapy: an update on current approaches
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies
D Liu, X Dai, L Ye, H Wang, H Qian… - Wiley …, 2023 - Wiley Online Library
Glioblastoma multiforme (GBM) represents the most common and fatal form of primary
invasive brain tumors as it affects a great number of patients each year and has a median …
invasive brain tumors as it affects a great number of patients each year and has a median …
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress
Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …
TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation
MM Suzuki, K Iijima, K Ogami, K Shinjo… - Nature …, 2023 - nature.com
Oncogene-induced DNA replication stress (RS) and consequent pathogenic R-loop
formation are known to impede S phase progression. Nonetheless, cancer cells …
formation are known to impede S phase progression. Nonetheless, cancer cells …
Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets
Antibody delivery to the CNS remains a huge hurdle for the clinical application of antibodies
targeting a CNS antigen. The blood–brain barrier and blood–CSF barrier restrict access of …
targeting a CNS antigen. The blood–brain barrier and blood–CSF barrier restrict access of …
Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma
AB Zhang, K Mozaffari, B Aguirre, V Li, R Kubba… - Cancers, 2023 - mdpi.com
Simple Summary Glioblastoma is the most common malignant primary brain tumor. Despite
technological advancements and modern therapeutic agents used for treatment, the …
technological advancements and modern therapeutic agents used for treatment, the …